Your browser version is outdated. We recommend that you update your browser to the latest version.

Welcome to MonTa Biosciences Aps

We development a novel cancer immunotherapy treatment based on systemic delivery of a novel TLR7 formulation

Our vision is to activate the innate immune system to educate the immune system to fight metastatic disease in patients with advanced cancer.

We have demonstrated strong anti-tumor activity in preclinical models with complete cure of up to 100 % of treated animals. Upon rechallenge with the same tumor cells more than 90 % of complete responders can fight a secondary tumor without additional treatment. This demonstrates the immune system is educated to recognize and eliminate tumor cells. 

We can provide targeting of our TLR7 agonist to the intracellular located TLR7 receptor in endosomes of immune cells to stimulate an innate immune response.